- Home
- NBTB vs RCKT Comparison
NBTB vs RCKT Comparison
Compare NBTB & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTB
- RCKT
- Stock Information
- Founded
- NBTB 1856
- RCKT 1999
- Country
- NBTB United States
- RCKT United States
- Employees
- NBTB N/A
- RCKT N/A
- Industry
- NBTB Major Banks
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- NBTB Finance
- RCKT Health Care
- Exchange
- NBTB Nasdaq
- RCKT Nasdaq
- Market Cap
- NBTB 2.2B
- RCKT 264.0M
- IPO Year
- NBTB N/A
- RCKT N/A
- Fundamental
- Price
- NBTB $43.82
- RCKT $2.99
- Analyst Decision
- NBTB Buy
- RCKT Buy
- Analyst Count
- NBTB 4
- RCKT 13
- Target Price
- NBTB $51.00
- RCKT $18.50
- AVG Volume (30 Days)
- NBTB 235.2K
- RCKT 3.8M
- Earning Date
- NBTB 07-28-2025
- RCKT 08-04-2025
- Dividend Yield
- NBTB 3.10%
- RCKT N/A
- EPS Growth
- NBTB 17.05
- RCKT N/A
- EPS
- NBTB 3.03
- RCKT N/A
- Revenue
- NBTB $569,473,000.00
- RCKT N/A
- Revenue This Year
- NBTB $26.51
- RCKT N/A
- Revenue Next Year
- NBTB $12.04
- RCKT N/A
- P/E Ratio
- NBTB $14.49
- RCKT N/A
- Revenue Growth
- NBTB 13.26
- RCKT N/A
- 52 Week Low
- NBTB $37.31
- RCKT $2.19
- 52 Week High
- NBTB $52.44
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- NBTB 61.42
- RCKT 45.55
- Support Level
- NBTB $42.23
- RCKT $2.76
- Resistance Level
- NBTB $44.25
- RCKT $3.24
- Average True Range (ATR)
- NBTB 1.05
- RCKT 0.19
- MACD
- NBTB 0.30
- RCKT 0.17
- Stochastic Oscillator
- NBTB 90.71
- RCKT 74.85
About NBTB NBT Bancorp Inc.
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.